Pharmacokinetics of Ganciclovir after Oral Valganciclovir versus Intravenous Ganciclovir in Allogeneic Stem Cell Transplant Patients with Graft-versus-Host Disease of the Gastrointestinal Tract

Biology of Blood and Marrow Transplantation

Volumn 12, Issue 6, 2006, Pages 635-640

  Winston, Drew J ^a   Baden, Lindsey R ^b   Gabriel, Don A ^c   Emmanouilides, Christos ^a   Shaw, Leslie M ^d   Lange, W Robert ^e   Ratanatharathorn, Voravit ^f  

^a UCLA MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e HOFFMANN LA ROCHE INC   (United States)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Graft versus host disease; Pharmacokinetics; Valganciclovir

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; GANCICLOVIR; MYCOPHENOLIC ACID; RAPAMYCIN; TACROLIMUS; VALGANCICLOVIR;

ACUTE LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; AREA UNDER THE CURVE; ARTICLE; CHRONIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYTOMEGALOVIRUS INFECTION; DISEASE ACTIVITY; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; GASTROINTESTINAL DISEASE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HUMAN; INFECTION PREVENTION; LYMPHOMA; MALE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; SINGLE DRUG DOSE; STEM CELL TRANSPLANTATION; VISUAL FIELD DEFECT;

ADMINISTRATION, ORAL; ADULT; ANTIVIRAL AGENTS; FEMALE; GANCICLOVIR; GASTROINTESTINAL DISEASES; GRAFT VS HOST DISEASE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 33646784682     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2005.12.038     Document Type: Article

References (21)

1. Boeckh M., Gooley T.A., Myerson D., Cunningham T., Schoch G., and Bowden R.A. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation. a randomized double-blind study. Blood 88 (1996) 4063-4071
2. Einsele H., Ehninger G., Hebart H., et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 86 (1995) 2815-2820
3. Goodrich J.M., Bowden R.A., Fisher L., Keller C., Schoch G., and Meyers J.D. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 118 (1993) 173-178
4. Winston D.J., Ho W.G., Bartoni K., et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann Intern Med 118 (1993) 179-184
5. Boeckh M., Zia J.A., Jung D., Skettino S., Chauncey T.R., and Bowden R.A. A study of the pharmacokinetics, antiviral activity, and tolerability of oral ganciclovir for CMV prophylaxis in marrow transplantation. Biol Blood Marrow Transplant 4 (1998) 13-19
6. Jung D., and Dorr A. Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects. J Clin Pharmacol 39 (1999) 800-804
7. Pescovitz M.D., Rabkin J., Merion R.M., et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 44 (2000) 2811-2815
8. Brown F., Banken L., Saywell K., and Arum I. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV and CMV-seropositive volunteers. Clin Pharmacokinet 37 (1999) 167-176
9. McDonald G.B., Shulman H.M., Sullivan K.M., and Spencer G.D. Intestinal and hepatic complications of human bone marrow transplantation. Gastroenterology 90 (1986) 460-477 770-784
10. Atkinson K., Biggs J.C., Britton K., et al. Oral administration of cyclosporin A for recipients of allogeneic marrow transplants. implications of clinical gut dysfunction. Br J Haematol 56 (1984) 223-231
11. Thomas E.D., Storb R., Clift R.A., et al. Bone-marrow transplantation. N Engl J Med 292 (1975) 895-902
12. Ratanatharathorn V., Ayash L., Lazarus H.M., Fu J., and Uberti J.P. Chronic graft-versus-host disease. clinical manifestations and therapy. Bone Marrow Transplant 28 (2001) 121-129
13. Chu F., Kiang C.H., Sung M.L., Huang B., Reeve R.L., and Tarnowski T. A rapid, sensitive HPLC method for the determination of ganciclovir in human plasma and serum. J Pharm Biomed Anal 21 (1999) 657-667
14. Chan R., LaFargue J., Reeve R.L., Tam Y., and Tarnowski T. An HPLC method for the determination of diastereomeric prodrug RS-79070-004 in human plasma. J Pharm Biomed Anal 21 (1999) 647-656
15. Wiltshire H., Hirankarn S., Farrell C., et al. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. Clin Pharmacokinet 44 (2005) 495-507
16. Einsele H., Reusser P., Hebart H., et al. Pharmacokinetics of valganciclovir after alloSCT. a fixed oral dose can be used for preemptive therapy in patients with normal body weight-even with intestinal GVHD. [abstract 2239]. Blood 104 (2004) 615a
17. Boeckh M., Leisenring W., Riddell S.R., et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants. importance of viral load and T-cell immunity. Blood 101 (2003) 407-414
18. Martin D.F., Sierra-Madero J., Walmsley S., et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med 346 (2002) 1119-1126
19. Paya C., Humar A., Dominguez E., et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 4 (2004) 611-620
20. Singh N., Wannstedt C., Keyes L., Gayowski T., Wagener M.M., and Cacciarelli T.V. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients. impact on viral load and late-onset cytomegalovirus disease. Transplantation 79 (2005) 85-90
21. Leather H.L., Meyer C.L., and Wingard J.R. Oral valganciclovir for preemptive therapy of cytomegalovirus antigenemia in hematopoietic stem cell transplant recipients. [abstract 238]. Biol Blood Marrow Transplant 9 (2003) 132